Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Alan J. Levy Sells 2,000 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the sale, the director now directly owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $375.01 on Thursday. The firm has a market cap of $133.02 billion, a P/E ratio of 67.69, a P/E/G ratio of 4.83 and a beta of 1.36. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The firm has a 50-day simple moving average of $386.40 and a two-hundred day simple moving average of $345.19.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same period in the previous year, the business posted $1.00 earnings per share. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 4.84 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on ISRG shares. Citigroup raised their target price on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Piper Sandler raised their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research report on Friday, April 19th. Truist Financial increased their price target on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. BTIG Research increased their price target on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research note on Friday, April 19th. Finally, Mizuho increased their price target on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $396.17.

Institutional Trading of Intuitive Surgical

Large investors have recently made changes to their positions in the stock. OFI Invest Asset Management bought a new stake in shares of Intuitive Surgical in the third quarter worth approximately $25,000. Baystate Wealth Management LLC boosted its holdings in shares of Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 45 shares during the last quarter. MCF Advisors LLC boosted its holdings in shares of Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 40 shares during the last quarter. Headinvest LLC purchased a new position in shares of Intuitive Surgical in the third quarter worth approximately $28,000. Finally, Able Wealth Management LLC purchased a new position in shares of Intuitive Surgical in the fourth quarter worth approximately $28,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.